Retinnovate 2025: Equipping Retinal Disease Innovators for Market Success
| November 13th – 14th
|
Overview: We’re excited to share that Paul Ryb, Managing Director at Outcome Capital, will be speaking at Retinnovate 2025: Equipping Retinal Disease Innovators for Market Success, taking place November 13–14 at Riddell Hall, Queen’s University Belfast.Paul will present on the UK ophthalmic innovation landscape, focusing on the critical gap between early-stage breakthroughs and the funding pathways required to bring them to market. Drawing from Outcome Capital’s deep sector knowledge, he’ll address how innovators can bridge the space between grant funding and the capital needed to achieve both patient impact and investor returns.This is an essential session for researchers, founders, and investors working at the intersection of eye health and innovation commercialization. Learn more and register: https://www.flowcoevents.com/retinnovate #Retinnovate2025 #Ophthalmology #MedTech #LifeSciences #OutcomeCapital #HealthcareInnovation #VentureFunding #StartupGrowth #InvestmentBanking #RetinalDisease #EyeHealth #UKInnovation #TechTransfer |
News
Outcome Capital Launches Pharmacy and Related Services Advisory Board to Advance Innovation Across the Healthcare Sector
Thom Stambaugh, recognized leader in pharmacy innovation and care delivery transformation, will serve as inaugural member Boston, MA – November 12, 2025 — Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced the formation of its Pharmacy and Related Services Advisory Board, a new initiative within the […]
Read MoreResources
Outcome Capital Life Science Market Pulse, October 2025
Outcome Capital Life Science Market Pulse October 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
